Literature DB >> 34078958

Mycoplasma pneumoniae CARDS toxin exploits host cell endosomal acidic pH and vacuolar ATPase proton pump to execute its biological activities.

Kumaraguruparan Ramasamy1, Sowmya Balasubramanian1, Alejandra Kirkpatrick1, Daniel Szabo1, Lavanya Pandranki1, Joel B Baseman1, T R Kannan2.   

Abstract

Mycoplasma pneumoniae is the leading cause of bacterial community-acquired pneumonia among hospitalized children in the United States. It is also responsible for a spectrum of other respiratory tract disorders and extrapulmonary manifestations in children and adults. The main virulence factor of M. pneumoniae is a 591 amino acid multifunctional protein called Community Acquired Respiratory Distress Syndrome (CARDS) toxin. The amino terminal region of CARDS toxin (N-CARDS) retains ADP-ribosylating activity and the carboxy region (C-CARDS) contains the receptor binding and vacuolating activities. After internalization, CARDS toxin is transported in a retrograde manner from endosome through the Golgi complex into the endoplasmic reticulum. However, the mechanisms and criteria by which internalized CARDS toxin is transported and activated to execute its cytotoxic effects remain unknown. In this study, we used full-length CARDS toxin and its mutant and truncated derivatives to analyze how pharmacological drugs that alter pH of intracellular vesicles and electrical potential across vesicular membranes affect translocation of CARDS toxin in mammalian cells. Our results indicate that an acidic environment is essential for CARDS toxin retrograde transport to endoplasmic reticulum. Moreover, retrograde transport facilitates toxin clipping and is required to induce vacuole formation. Additionally, toxin-mediated cell vacuolation is strictly dependent on the function of vacuolar type-ATPase.

Entities:  

Year:  2021        PMID: 34078958     DOI: 10.1038/s41598-021-90948-3

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  35 in total

1.  Synthesis and distribution of CARDS toxin during Mycoplasma pneumoniae infection in a murine model.

Authors:  T R Kannan; Jacqueline J Coalson; Marianna Cagle; Oxana Musatovova; R Doug Hardy; Joel B Baseman
Journal:  J Infect Dis       Date:  2011-09-28       Impact factor: 5.226

2.  Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among mycoplasma pneumoniae strains.

Authors:  Chonnamet Techasaensiri; Claudia Tagliabue; Marianna Cagle; Pooya Iranpour; Kathy Katz; Thirumalai R Kannan; Jacqueline J Coalson; Joel B Baseman; R Doug Hardy
Journal:  Am J Respir Crit Care Med       Date:  2010-05-27       Impact factor: 21.405

Review 3.  Mycoplasma pneumoniae Infections in Childhood.

Authors:  T Prescott Atkinson; Ken B Waites
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

4.  Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.

Authors:  Seema Jain; Wesley H Self; Richard G Wunderink; Sherene Fakhran; Robert Balk; Anna M Bramley; Carrie Reed; Carlos G Grijalva; Evan J Anderson; D Mark Courtney; James D Chappell; Chao Qi; Eric M Hart; Frank Carroll; Christopher Trabue; Helen K Donnelly; Derek J Williams; Yuwei Zhu; Sandra R Arnold; Krow Ampofo; Grant W Waterer; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Jonathan A McCullers; Andrew T Pavia; Kathryn M Edwards; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-07-14       Impact factor: 91.245

Review 5.  Mycoplasma pneumoniae from the Respiratory Tract and Beyond.

Authors:  Ken B Waites; Li Xiao; Yang Liu; Mitchell F Balish; T Prescott Atkinson
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

6.  Novel toxin assays implicate Mycoplasma pneumoniae in prolonged ventilator course and hypoxemia.

Authors:  Mark T Muir; Stephen M Cohn; Christopher Louden; Thirumalai R Kannan; Joel B Baseman
Journal:  Chest       Date:  2010-09-30       Impact factor: 9.410

7.  Community-acquired pneumonia requiring hospitalization among U.S. children.

Authors:  Seema Jain; Derek J Williams; Sandra R Arnold; Krow Ampofo; Anna M Bramley; Carrie Reed; Chris Stockmann; Evan J Anderson; Carlos G Grijalva; Wesley H Self; Yuwei Zhu; Anami Patel; Weston Hymas; James D Chappell; Robert A Kaufman; J Herman Kan; David Dansie; Noel Lenny; David R Hillyard; Lia M Haynes; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Richard G Wunderink; Kathryn M Edwards; Andrew T Pavia; Jonathan A McCullers; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-02-26       Impact factor: 91.245

8.  ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens.

Authors:  T R Kannan; Joel B Baseman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-14       Impact factor: 11.205

Review 9.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  Mycoplasma pneumoniae Community Acquired Respiratory Distress Syndrome toxin expression reveals growth phase and infection-dependent regulation.

Authors:  T R Kannan; Oxana Musatovova; Sowmya Balasubramanian; Marianna Cagle; Jarrat L Jordan; Thomas M Krunkosky; Alan Davis; Robert D Hardy; Joel B Baseman
Journal:  Mol Microbiol       Date:  2010-02-28       Impact factor: 3.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.